# Lealing Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lealing-biopharma

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Latest round: Angel (Nov 1, 2022)
- Investors on record: 2

## About

Based in Suzhou, China and established in 2020, Lealing Biopharma operates as a biopharmaceutical developer that focuses on personalized TCR-T cell therapy and TCR dual anti-drugs R&D. Hongchuan Liu is the co-founder of the company, he once served as the head of quality management department of Shanghai Junshi Biosciences Co., Ltd. And Wenbo Wang is the founder of the company, he used to study in German Cancer Research Center, Jackson Lab, CARL JUNE Lab and Shanghai Ruijin Hospital.

The company provides personalized TCR-T cell therapy and TCR dual anti-drugs. Its technology platforms include TCR rapid cloning and screening technology, multiple optimized aAPC models, immune cells secreting single-domain antibodies and optimized TCR dual antibody structure.

## Funding rounds

- Angel, Nov 1, 2022 — YuanBio Venture, Bohe Angel Fund

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel
- Bohe Angel Fund — Angel